Omada Health's Customer Concentration Problem Hasn't Gone Away Since Going Public

Omada Health Inc (OMDA) reports Q2 2026 earnings after market close on August 6, 2026, with analysts expecting the digital health company to approach breakeven after a year of dramatic profitability improvements. The central question is whether management can sustain the momentum that drove three consecutive earnings beats while delivering on raised full-year guidance that implies approximately 25% revenue growth.

Part 1: Earnings Preview

Omada Health operates a digital care platform focused on chronic disease management, particularly diabetes prevention and weight management, serving employers, health plans, and healthcare systems through virtual coaching and connected devices. The company has emerged as a leader in value-based care delivery, with recent partnerships including Optum RX and Eli Lilly's Employer Connect program expanding its addressable market.

For Q2 2026, analysts expect EPS of -$0.01 (consensus of 2 estimates ranging from -$0.03 to $0.00), representing a +95.45% improvement versus the -$0.22 loss reported in Q2 2025. The most recently reported quarter (Q1 2026) delivered EPS of -$0.05, beating the -$0.08 estimate by 37.50%. Revenue for Q2 is estimated at approximately $80 million based on the raised full-year guidance of $322-330 million.

Three key themes define this earnings story:

Path to Profitability: Omada's trajectory from consistent losses to near-breakeven represents the most critical narrative. The company achieved positive adjusted EBITDA of $1 million in Q1 2026 and raised full-year adjusted EBITDA guidance to $14-20 million (from $7-15 million), representing nearly a threefold improvement versus 2025. Investors will scrutinize whether Q2 continues this trend and whether the company can sustain profitability as it scales.

Margin Expansion and Operating Leverage: GAAP gross margin improved to 62% in Q1 2026 from 58% in Q1 2025, with management signaling confidence in exceeding the current long-term target of 70%. The ability to drive margin expansion while maintaining 25% revenue growth demonstrates operational leverage that could accelerate earnings power. An investor day planned for September 2026 may provide updated long-term targets.

Enterprise Partnership Momentum: New channel partnerships with Optum RX and Lilly Employer Connect are not expected to contribute materially to 2026 revenue but signal significant 2027 upside potential. Management's confidence in raising guidance despite these partnerships being largely excluded from current-year projections suggests strong underlying business momentum. Tracking clinical outcomes data and large enterprise contract wins will be critical to validating the company's competitive positioning.

Analysts have grown increasingly bullish heading into the release, with consensus estimates rising sharply over the past 90 days. The Q2 estimate improved from $0.00 three months ago to -$0.01 currently, while full-year 2026 estimates jumped from -$0.35 to -$0.01, and 2027 estimates surged from -$0.01 to $0.14 (implying +1,500% growth). This dramatic revision pattern reflects growing confidence in Omada's business inflection.

Part 2: Historical Earnings Performance

Omada Health has established a strong pattern of earnings beats over the past four quarters, consistently exceeding analyst expectations despite volatile estimate ranges. The company delivered a +37.50% beat in Q1 2026 (reporting -$0.05 versus -$0.08 estimated), a +300.00% beat in Q4 2025 (reporting $0.08 versus -$0.04 estimated), and a +87.50% beat in Q3 2025 (reporting -$0.03 versus -$0.24 estimated). The only miss came in Q2 2025, when the company reported -$0.22 versus -$0.15 estimated, a -46.67% shortfall.

The trend shows dramatic improvement in profitability trajectory. After the Q2 2025 miss that saw losses deepen, Omada executed a sharp turnaround with three consecutive quarters of better-than-expected results. Most notably, Q4 2025 marked the company's first profitable quarter with $0.08 in earnings, crushing expectations for a -$0.04 loss. While Q1 2026 returned to a small loss, the -$0.05 result still beat estimates and represented significant year-over-year improvement from the -$0.22 loss in Q2 2025.

This pattern of consistent beats—averaging well over 100% positive surprise in the past three quarters—suggests management has successfully reset the business model and may be guiding conservatively. The magnitude of beats has been particularly pronounced when analysts expected losses, indicating the company's path to profitability is accelerating faster than Wall Street anticipated.

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Omada Health reports after market close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's first full reaction to the actual earnings data.

Historical price behavior shows moderate volatility around earnings, with an average absolute Day 0 move of 2.56% and Day +1 move of 5.58%. The Day +1 reaction has been more significant, averaging more than double the Day 0 anticipatory move, suggesting investors wait for actual results before making major positioning changes.

The most recent earnings (Q1 2026 on May 7) saw a muted Day 0 gain of 3.40% followed by a sharp Day 1 decline of 9.63%, despite the company beating estimates and raising guidance. This pattern suggests profit-taking after a strong run-up or concerns about the pace of improvement. The prior quarter (Q4 2025) showed minimal Day 0 movement but a solid 3.31% Day 1 gain. The largest reaction came in Q3 2025, with a 6.14% Day 0 decline and 7.13% Day 1 drop, coinciding with the period before the company's turnaround became evident.

Investors should anticipate meaningful post-earnings volatility, with the Day 1 range averaging 14.14%, indicating the stock can swing significantly as the market digests results and guidance. The pattern suggests OMDA tends to see its largest moves on the day after earnings are released rather than in anticipatory trading.

Part 2.2: Options Market Expected Move

The options market is pricing an 8.72% expected move for the August 21 expiration, which is notably higher than the average historical Day 0 move of 2.56% but below the average Day 1 move of 5.58%. The expected move falls well short of the average Day 1 range of 14.14%, suggesting options may be underpricing potential volatility given OMDA's recent history of significant post-earnings swings.

Part 3: What Analysts Are Saying

Analyst sentiment on Omada Health is decidedly bullish, with a consensus rating of 4.43 out of 5.0 (between Buy and Strong Buy) and an average price target of $25.31, implying 32% upside from the current price of $19.11. The Street's conviction has strengthened recently, with sentiment having improved over the past month as one additional analyst upgraded to Strong Buy.

The rating breakdown shows overwhelming bullish positioning: 9 Strong Buys (up from 8 a month ago), 2 Moderate Buys, and 3 Holds, with zero sell ratings among the 14 analysts covering the stock. This 11-to-3 buy-to-hold ratio reflects broad confidence in the company's business inflection and path to sustained profitability.

Price targets range from a low of $15.00 to a high of $30.00, with the high-end target suggesting 57% upside potential. Even the most conservative $15.00 target sits only 21% below current levels, indicating limited downside risk in analysts' models. The tight clustering of bullish ratings and the recent upgrade activity suggest the Street views Omada's Q1 results and raised guidance as validation of an accelerating growth trajectory, with the upcoming investor day in September potentially serving as a catalyst for further target increases if management provides ambitious long-term targets.

Part 4: Technical Picture

Omada Health's technical setup heading into earnings shows mixed signals, with the stock trading below most short-term moving averages but maintaining gains above longer-term trend lines. The Barchart Technical Opinion currently registers a 56% Buy signal, down from 88% Buy a month ago but improved from 40% Buy last week, indicating recent stabilization after a period of weakness.

The stock is trading at $19.11, positioned below the 5-day ($19.87), 10-day ($20.17), 20-day ($21.76), and 50-day ($20.06) moving averages, but above the 100-day ($17.14) and 200-day ($16.98) moving averages. This configuration suggests near-term consolidation or pullback from recent highs while the longer-term uptrend remains intact.

Timeframe Analysis:

• Short-term (50% Buy): Moderate buy signal indicates near-term momentum has cooled from recent strength but remains constructive
• Medium-term (50% Buy): Neutral-to-positive reading suggests the intermediate trend is in a consolidation phase
• Long-term (100% Buy): Strong buy signal confirms the broader uptrend remains firmly intact despite recent weakness

Trend Characteristics: The technical environment shows Average strength with the Weakest directional momentum, suggesting the stock is in a consolidation phase within an established uptrend heading into earnings.

The recent pullback from the 20-day moving average has created a technical setup where a strong earnings beat could trigger a breakout back above near-term resistance levels, while a disappointment could test support at the 100-day and 200-day moving averages around $17. The fact that longer-term indicators remain bullish while short-term momentum has faded suggests the stock has digested recent gains and may be coiled for a significant post-earnings move in either direction.

Key technical levels to watch include resistance at the 20-day moving average of $21.76, which has capped recent rallies, and support at the 100-day moving average of $17.14, which has provided a floor during the 2026 uptrend. The stock's position above both the 100-day and 200-day moving averages confirms the longer-term bullish structure remains intact, while trading below shorter-term averages suggests the market is waiting for earnings confirmation before committing to the next leg higher. The overall technical setup is cautiously supportive—the pullback has reduced overbought conditions and created room for upside, but the stock will need to deliver a strong earnings beat and confident guidance to reclaim near-term momentum and challenge the $21-22 resistance zone.